CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Lansoprazole (Prevacid)drug
Likely dose
Lansoprazole 30–450 mg daily, individualized based on gastric acid productionAI-extracted
Key inclusion· 1
  • ✓Diagnosed with Zollinger-Ellison syndrome
Key exclusion· 1
  • ✕Pregnant or lactating females

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00204373
NCT00204373Phase 4Completed
CompareCT.gov

Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors

Charles Mel Wilcox, MD·interventional·Posted Sep 20, 2005·Updated Oct 30, 2012

In Brief

A Phase 4 clinical trial evaluating Lansoprazole (Prevacid) for Zollinger-Ellison Syndrome and Multiple Endocrine Neoplasia. Completed, enrolled 72 participants.

Detailed Summary

The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsZollinger-Ellison Syndrome, Multiple Endocrine Neoplasia
Countries--
CollaboratorsTakeda Pharmaceuticals North America, Inc.

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartMar 1, 2003
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 20.8 years ago

Interventions

Lansoprazole (Prevacid)drug

Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.